- Home
- CVKD vs CRIS Comparison
CVKD vs CRIS Comparison
Compare CVKD & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- CRIS
- Stock Information
- Founded
- CVKD 2022
- CRIS 2000
- Country
- CVKD United States
- CRIS United States
- Employees
- CVKD N/A
- CRIS N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVKD Health Care
- CRIS Health Care
- Exchange
- CVKD Nasdaq
- CRIS Nasdaq
- Market Cap
- CVKD 27.0M
- CRIS 22.9M
- IPO Year
- CVKD 2023
- CRIS 2000
- Fundamental
- Price
- CVKD $14.13
- CRIS $1.61
- Analyst Decision
- CVKD Strong Buy
- CRIS Strong Buy
- Analyst Count
- CVKD 1
- CRIS 2
- Target Price
- CVKD $32.00
- CRIS $16.50
- AVG Volume (30 Days)
- CVKD 25.8K
- CRIS 72.2K
- Earning Date
- CVKD 11-07-2025
- CRIS 11-13-2025
- Dividend Yield
- CVKD N/A
- CRIS N/A
- EPS Growth
- CVKD N/A
- CRIS N/A
- EPS
- CVKD N/A
- CRIS N/A
- Revenue
- CVKD N/A
- CRIS $11,405,000.00
- Revenue This Year
- CVKD N/A
- CRIS $2.72
- Revenue Next Year
- CVKD N/A
- CRIS $8.27
- P/E Ratio
- CVKD N/A
- CRIS N/A
- Revenue Growth
- CVKD N/A
- CRIS 12.24
- 52 Week Low
- CVKD $8.74
- CRIS $1.02
- 52 Week High
- CVKD $22.90
- CRIS $5.27
- Technical
- Relative Strength Index (RSI)
- CVKD 54.38
- CRIS 50.58
- Support Level
- CVKD $12.11
- CRIS $1.49
- Resistance Level
- CVKD $14.35
- CRIS $1.63
- Average True Range (ATR)
- CVKD 0.66
- CRIS 0.10
- MACD
- CVKD -0.08
- CRIS 0.01
- Stochastic Oscillator
- CVKD 76.99
- CRIS 68.87
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.